CliffBio
small molecule

RASONQUE

DARAXONRASIB

Loss of exclusivityJanuary 2042latest FDA-listed patent expiry
CompanyREVOLUTION MEDICINES INC

Drug detail

Brand nameRASONQUE
Active ingredientDARAXONRASIB
Strength100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2026
Marketing statusRX

Listed patents

PatentExpiresType
12280113January 2042substance, product
12403196September 2041substance, product

Regulatory exclusivity

CodeExpires
NCEAugust 2031

More from REVOLUTION MEDICINES INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.